Carboplatin (AUC 5)

DRUG8 trials

Sponsors

Eli Lilly and Company, FBD Biologics Limited, Xijing Hospital, Intergroupe Francophone de Cancerologie Thoracique, Akeso

Conditions

Advanced Gynecological MalignanciesCarcinoma, Non-Small-Cell LungExtensive-stage Small Cell Lung Cancer (ES-SCLC)Fallopian Tube CancersHigh-grade Serous Ovarian Cancer (HGSOC)Locally Advanced Non-Small Cell Lung CancerPleural MesotheliomasPrimary Peritoneal Cancer

Phase 1

Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors

Active, not recruitingNCT06771622

FBD Biologics LimitedSolid Cancer

Start: 2025-03-13End: 2029-01-01Target: 500Updated: 2026-02-04

A Study of QL1706 Combined With Short-Cycle Anthracyclines or Taxanes for the Treatment of Early-Stage TNBC

RecruitingNCT07178171

Xijing HospitalTNBC, Triple Negative Breast Cancer

Start: 2025-11-06End: 2030-08-01Target: 30Updated: 2025-11-24

Phase 2

A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC)

CompletedNCT01160744

Eli Lilly and CompanyCarcinoma, Non-Small-Cell Lung

Start: 2010-09-30End: 2018-04-30Updated: 2019-09-13

Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma

Not yet recruitingNCT07234058

Intergroupe Francophone de Cancerologie ThoraciquePleural Mesotheliomas

Start: 2026-02-01End: 2029-09-01Target: 126Updated: 2026-02-11

A Study of Ivonescimab in First-Line ES-SCLC

RecruitingNCT07245446

AkesoExtensive-stage Small Cell Lung Cancer (ES-SCLC)

Start: 2025-10-29End: 2028-06-30Target: 180Updated: 2025-11-24

Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC

Not yet recruitingNCT07309952

Yang HongLocally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer

Start: 2025-12-31End: 2032-10-31Target: 28Updated: 2025-12-30

Neoadjuvant Aitua (PD-1/CTLA-4 Bispecific) Plus Nab-Paclitaxel and Carboplatin for Advanced High-Grade Serous Ovarian Cancer

Not yet recruitingNCT07432594

Cancer Institute and Hospital, Chinese Academy of Medical SciencesFallopian Tube Cancers, High-grade Serous Ovarian Cancer (HGSOC), Primary Peritoneal Cancer

Start: 2026-03-01End: 2027-06-30Target: 82Updated: 2026-02-25

A Study of SKB518 as Monotherapy or Combination Therapy in Patients With Advanced Gynecological Malignant Tumors

Not yet recruitingNCT07448922

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.Advanced Gynecological Malignancies

Start: 2026-03-25End: 2028-09-30Target: 290Updated: 2026-03-04

Related Papers

Abstract B076: Phase 1 Monotherapy and Combination Data for HCB101, a Novel SIRPα–Fc Innate Checkpoint Fusion Protein

Cancer Immunology Research2026-02-18

Dose-dependent antitumor activity of HCB101 plus ramucirumab and paclitaxel in previously treated gastric cancer.

Journal of Clinical Oncology2026-01-10